Author

Peter C. Sennhenn

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

Aditi Swamy· 1 shared Adrian R. KraineriD· 1 shared Anand VasudevaniD· 1 shared Andrew Chatr‐aryamontriiD· 1 shared Brianna E. MendelsoniD· 1 shared Claudio Chuaqui· 1 shared David L. SpectoriD· 1 shared Devon A. LukowiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aditi Swamy

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

On-target toxicity limits the efficacy of CDK11 inhibition against cancers with 1p36 deletions

Linda Julian, Lisa Crozier, Devon A. Lukow, Sanat Mishra, Aditi Swamy, Ryan A. Hagenson, Peter C. Sennhenn, Erin L. Sausville, Brianna E. Mendelson, Claudio Chuaqui, Lu Qiao, Anand Vasudevan, Kuan‐Ting Lin, Sonam Bhatia, Thierry Bertomeu, , Jason M. Sheltzer

This study shows CDK11 is critical for cancer cell survival and identifies 1p36 deletions as a biomarker for CDK11 inhibitor sensitivity, but on-target toxicity limits therapeutic efficacy.

bioRxiv · Aug 3, 2025 · PreprintCancer Biology